Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked diligently but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last several shares of mine. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire job interview that I came away with a bad opinion of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, however, the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this expertise and associated intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) and the first new drug application approval ($five million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it has this individual treatment in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on the website of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple presentations in addition to multiple publications.

Might it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very start of my interest in this particular business. Judging with the multiples of thousands of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *